Cancer Supportive Care Product Market
Cancer Supportive Care Product Market Study by Anti-Emetics, Anti-Infective, Bisphosphonates, Monoclonal Antibodies, Nonsteroidal Anti Inflammatory Drugs, and Opioid Analgesics from 2024 to 2034
Analysis of Cancer Supportive Care Product Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cancer Supportive Care Product Market Outlook (2024 to 2034)
The global cancer supportive care product market is projected to increase from a value of US$ 35.47 billion in 2024 to US$ 68.93 billion by the end of 2034. Worldwide sales of cancer-supportive care products are forecasted to rise at a CAGR of 6.9% from 2024 to 2034.
Cancer is widely known for its severity and the significant side effects it can cause. Fortunately, cancer supportive care products help mitigate these side effects, enabling patients to receive necessary treatment more easily. Physicians often recommend starting cancer supportive care medications immediately following a diagnosis. According to the National Cancer Institute, these medications positively impact both mental and physical health.
Evidence shows that supportive care medications play a crucial role in post-therapy treatment for cancer patients. They help patients avoid side effects and alleviate cancer-related complications. Chemotherapy, one of the most effective cancer treatments, can lead to increased toxicity and reduced quality of life over time. Supportive care medications address these side effects, contributing to the expansion of the cancer supportive care product market size.
Most professionals, including therapists, dietitians, pain management specialists, palliative care experts, and medical advisors, deliver supportive cancer care medications or sessions. These medications can improve patient outcomes and quality of life.
- The National Cancer Institute estimates that by the end of 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected. This high incidence rate drives the demand for cancer supportive care products, as more people seek to mitigate side effects.
- The World Cancer Research Fund International (WCRF) predicts over 24 million new cancer cases by 2035, excluding skin cancer.
- In 2017, the National Cancer Institute (NIH) reported over 1.5 million new cancer cases in the United States.
The rising number of cases will lead to an increased need for chemotherapy and radiation therapy. These therapies often have side effects that cancer-supportive care products help mitigate. All of these factors are contributing to global cancer supportive care product market growth.
| Report Attribute | Detail |
|---|---|
| Cancer Supportive Care Product Market Size (2024E) | US$ 35.47 Billion |
| Forecasted Market Value (2034F) | US$ 68.93 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.9% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 7.5% CAGR |
| China Market Value (2034F) | US$ 6.08 Billion |
| North America Market Share (2024E) | 37.7% |
| East Asia Market Share (2034F) | 20.4% |
| Key Companies Profiled | Amgen Inc.; Baxter International Inc.; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc (GSK) (Tesaro); Helsinn Healthcare; Heron Therapeutics; Johnson & Johnson (Janssen Global Services, LLC); Merck KGAA; Novartis International AG (Sandoz); Bristol Myers Squibb Company; Eli Lilly and Company; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; AstraZeneca PLC; Bayer AG; GlaxoSmithKline Plc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What’s Increasing the Profitability of Cancer Care Product Suppliers?
“Rising Prevalence of Cancer Necessitating Chemotherapy and Leading to Severe Side Effects”
Globally, chemotherapy is the most commonly used cancer treatment. Traditional chemotherapy aims to eradicate cancer cells but often causes severe side effects such as anemia, mouth sores, nausea, vomiting, hair loss, and skin infections, which can be short-term or long-lasting. Supportive care medications for cancer patients significantly mitigate these harmful effects by protecting healthy cells and organs from the impact of cancer cells before they occur.
Cancer supportive care drugs reduce treatment side effects and enhance tolerance to aggressive therapies.
- In August 2021, the Centers for Medicare and Medicaid Innovation (CMMI) reported that patients using supportive care medications experienced fewer emergency room visits, hospital stays, and department visits.
With growing awareness of chemotherapy's adverse effects, the benefits of supportive cancer care medications are expected to drive market growth.
“Focus of Several Governments on Improving Cancer Awareness”
Governments worldwide are focusing on improving the oncology sector's overall infrastructure to provide cancer patients with high-quality healthcare services, driven by growing public health concerns. This is a key cancer supportive care product market trend. Investments in new cancer treatment centers and centralized procurement schemes are being made by various governments globally. For instance, England's 10-year long-term cancer strategy aims to significantly increase patient survival rates by 2028.
The Indian government is striving to increase the number of linear accelerators necessary for radiation therapy. This heightened governmental attention and investment in the oncology sector offer researchers numerous opportunities to develop innovative and advanced supportive care medications for cancer patients.
- The World Health Organization reports that significant new legislative, programmatic, and financial commitments, including nearly US$ 600 million in additional funding, were announced by governments, donors, multilateral organizations, and partners to eradicate cervical cancer.
What is Limiting the Market from Reaching its Full Potential?
“High Expenditure and Restriction on Opioid Pain Killer Use”
Cancer patients frequently use opioid medications to manage severe pain. Doctors often prescribe opioids to patients undergoing chemotherapy or other treatments for their supportive care benefits. However, due to their severe side effects–such as depression, osteoporosis, respiratory issues, development of other serious conditions, neurological consequences, and permanent brain damage–opioids are now less commonly prescribed.
Opioids can also lead to coma or death. Long-term use of opioids may result in infertility in women and erectile dysfunction in men, according to various clinical studies. In response to this ongoing public health crisis, numerous governments and health ministries are implementing stringent laws and regulations to limit or ban the prescription of opioids. These strict regulations on painkillers are likely to impede the growth of the cancer-supportive care product market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Cancer supportive care products are becoming popular in various countries including the United States, China, Canada, Japan, and South Korea. The markets in East Asia and North America are projected to expand at a CAGR of 7% from 2024 to 2034.
What is Leading to Significant Market Growth in Mexico?
“Government Initiatives Enhancing Access to Cancer Care”
| Attribute | Mexico |
|---|---|
| Market Value (2024E) | US$ 636 Million |
| Growth Rate (2024 to 2034) | 7.8% CAGR |
| Projected Value (2034F) | US$ 1.35 Billion |
The market for supportive care products in Mexico is expanding at a significant rate as a result of government programs targeted at enhancing access to cancer treatment and care. The use of supportive care products by healthcare practitioners may be encouraged or subsidized by these programs.
- Third-generation Mexican Americans have a 66% higher risk of liver cancer than first-generation Mexican Americans, according to research headed by the USC Keck School of Medicine. The 2023 study examined the disease's risk factor across over 30,000 Mexican Americans.
How are Market Players in China Able to Improve Their Profit margins?
“Regulatory Support and Guidelines Added with Patient-Centric Approach”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 2.73 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 6.08 Billion |
The importance of supportive care in cancer therapy has been highlighted in guidelines and procedures established by regulatory bodies and healthcare organizations. Adherence to these principles is driving the adoption of supportive care medications and their integration into routine cancer care regimens.
Category-wise Evaluation
Based on distribution channels, hospital pharmacies are poised to occupy a 74.6% cancer supportive care product market share in 2024.
What Primary Benefit Do Erythropoietin-Stimulating Agents (ESAs) Provide to Cancer Patients?
“ESAs Improving Oxygen Delivery to Tissues and Organs”
| Attribute | Erythropoietin Stimulating Agents |
|---|---|
| Segment Value (2024E) | US$ 8.76 Billion |
| Growth Rate (2024 to 2034) | 7% CAGR |
| Projected Value (2034F) | US$ 17.23 Billion |
Erythropoietin-stimulating agents (ESAs) are pharmaceuticals that promote the production of red blood cells in the body. One of the primary benefits of ESAs is their ability to treat anemia, particularly in cancer patients undergoing chemotherapy or those with chronic kidney disease. By boosting red blood cell production, ESAs enhance oxygen delivery to tissues and organs, thereby reducing feelings of weakness and fatigue.
Why are Supportive Care Products Extensively Used in Lung Cancer Treatment?
“Severity and Symptom Burden Associated with Lung Cancer”
| Attribute | Lung Cancer |
|---|---|
| Segment Value (2024E) | US$ 5.21 Billion |
| Growth Rate (2024 to 2034) | 7% CAGR |
| Projected Value (2034F) | US$ 10.22 Billion |
Among cancer patients undergoing therapy, lung cancer stands out as a critical indication for supportive care products. The specific needs of lung cancer patients drive the demand for specialized supportive care to manage symptoms and improve quality of life. Meeting these particular demands is essential to providing comprehensive care for lung cancer patients.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Business Rivalry
Key players in the cancer supportive care product industry are adapting themselves to key market trends such as monoclonal antibodies and cancer immunotherapy.
- The clinical-stage biotechnology company First Light Acquisition Group and Calidi Biotherapeutics, Inc., announced their merger in 2023. Their goal is to develop oncolytic virotherapy using a stem cell-based delivery system for cancer treatments.
- In December 2022, the FDA approved atezolizumab (Tecentriq), an immunotherapy drug, for treating Alveolar Soft Part Sarcoma (ASPS) in adults and children aged 2 and older if the disease has metastasized or is inoperable.
- Novartis received FDA approval in 2022 to use Pluvicto for treating adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously undergone chemotherapy with taxanes and androgen receptor pathway inhibitors.
- Gilead and Dragonfly announced their collaboration on natural killer cell engagers in cancer starting in 2022. As part of the agreement, Gilead acquired a global license from Dragonfly for their immunotherapy development DF7001, which targets 5T4.
Fact.MR provides detailed information about the price points of key cancer supportive care product manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Key Segments of Cancer Supportive Care Product Market Research
-
By Drug Class :
- Anti-Emetics
- Anti-Infective
- Bisphosphonates
- Erythropoietin Stimulating Agents
- Granulocyte Colony Stimulating Factor
- Monoclonal Antibodies
- Nonsteroidal Anti-Inflammatory Drugs
- Opioid Analgesics
-
By Indication :
- Bladder Cancer
- Breast Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Melanoma Cancer
- Ovary Cancer
- Prostate Cancer
- Others
-
By Distribution Channel :
- Compounding Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Drug Class 6.2. Indication 6.3. Distribution Channel 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class 7.1. Anti-Emetics 7.2. Anti-Infective 7.3. Bisphosphonates 7.4. Erythropoietin Stimulating Agents 7.5. Granulocyte Colony Stimulating Factor 7.6. Monoclonal Antibodies 7.7. Nonsteroidal Anti-Inflammatory Drugs 7.8. Opioid Analgesics 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication 8.1. Bladder Cancer 8.2. Breast Cancer 8.3. Leukemia 8.4. Liver Cancer 8.5. Lung Cancer 8.6. Melanoma Cancer 8.7. Ovary Cancer 8.8. Prostate Cancer 8.9. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 9.1. Compounding Pharmacies 9.2. Hospital Pharmacies 9.3. Retail Pharmacies 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia & Pacific 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Drug Class, Indication, Distribution Channel, and Region for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Amgen Inc. 20.2. Baxter International Inc. 20.3. Hoffmann-La Roche Ltd. 20.4. GlaxoSmithKline Plc (GSK) (Tesaro) 20.5. Helsinn Healthcare 20.6. Heron Therapeutics 20.7. Johnson & Johnson (Janssen Global Services, LLC) 20.8. Merck KGAA 20.9. Novartis International AG (Sandoz) 20.10. Bristol Myers Squibb Company 20.11. Eli Lilly and Company 20.12. Sanofi S.A. 20.13. Takeda Pharmaceutical Company Limited 20.14. Teva Pharmaceutical Industries Ltd. 20.15. AbbVie Inc. 20.16. AstraZeneca PLC 20.17. Bayer AG 20.18. GlaxoSmithKline Plc 21. Assumptions and Acronyms Drug Classd 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the size of the cancer supportive care product market in 2024?
The market for cancer supportive care products is estimated at US$ 35.47 billion in 2024.
What are the projections for the market through 2034?
The market is forecasted to expand at a CAGR of 6.9% to reach US$ 68.93 billion by 2034.
Who are the leading manufacturers of cancer supportive care products?
Leading market players are Amgen Inc., Baxter International Inc., and Hoffmann-La Roche Ltd.
What is the projected growth rate for the market in Japan?
The market in Japan is projected to advance at a CAGR of 7.1% between 2024 and 2034.
Which drug class is expected to account for a significant market share?
Sales of erythropoietin stimulating agents are evaluated to reach US$ 8.76 billion in 2024.
What are the projections for the United States market?
The U.S. market is projected to expand at a CAGR of 7% and reach a size of US$ 22.22 billion by 2034.
Cancer Supportive Care Product Market